What is Guardant Health's market cap?

Guardant Health (GH) has a market capitalization of $20.7B and trades on NASDAQ.

What is Guardant Health's revenue and profitability?

Guardant Health generated $1.1B in trailing twelve-month revenue with a net loss of $433.2M, representing a net margin of -40.1%. Gross margin stands at 64.9%, with free cash flow of -$237.1M. These figures are based on the Q1 2026 filing.

Who are Guardant Health's competitors?

Guardant Health's key competitors include Grail, Natera, Illumina, and others. These companies compete in similar markets and product categories.

Where is Guardant Health headquartered?

Guardant Health is headquartered in United States of America and employs approximately 1,779 people. It has been publicly traded since 2018.

Guardant Health

Guardant Health is a leading precision oncology company that develops advanced blood and tissue tests to provide critical insights across all stages of cancer care.

Market cap

$20.71B+231%

Revenue$1.1B+39.6%

Net income-$433.2M-4.0%

Free cash flow-$237.1M+22.2%

EPS (diluted)-$3.39—

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$301.7MBeat by $22.5M EPS-$0.85Miss by $0.38

Read the full report

Next report

Jul 29, 2026 (In 2 weeks)

Revenue estimate$314.2M

EPS estimate-$0.41

Financials

Q1 2026

Income statement

See full

Revenue$301.7M+48.3%

Gross profit$196.7M+52.8%

Operating income-$121.4M-9.3%

Net income-$112.1M-17.8%

EPS (diluted)-$0.85-10.4%

Balance sheet

See full

Cash & equivalents$1.1B+37.0%

Total debt$1.7B+30.5%

Total equity-$181.1M+27.8%

Total assets$1.9B+42.5%

Cash flow

See full

Operating cash flow-$65.6M-4.7%

CapEx$5.6M+25.1%

Free cash flow-$71.2M-6.0%

Valuation & ratios

Valuation

See full

Market cap$20.71B+231%

Enterprise value$21.31B+211%

P/S19.2×+11.6×

Profitability

See full

Gross margin64.9%+3.6pp

Operating margin-41.4%-9.4pp

Net margin-40.1%-8.1pp

FCF margin-22%-6.7pp

Returns & leverage

See full

Current ratio4.7×+0.6×

Segments

By product

See full

Oncology$205.0M+36.1%

Biopharma and data$53.0M+16.8%

Screening$41.6M+633%

Licensing and other$2.1M+15.3%

By segment

See full

Reportable Segment$301.7M+48.3%

Competitors

By market cap

Natera, Inc.$39.3B+77.9%

Illumina$28.4B+78.1%

Guardant Health$20.7B+231%

GRAIL, Inc.$3.0B+79.1%

NeoGenomics$1.9B+90.8%

Personalis, Inc.$1.5B+125%

Fulgent Genetics, Inc.$585.3M-4.2%

ADV

Advanced Biomed Inc. Common Stock$8.3M-43.5%

By revenue growth

Guardant Health+39.6%

Natera, Inc.+36.6%

GRAIL, Inc.+19.4%

NeoGenomics+11.0%

Fulgent Genetics, Inc.+9.5%

Illumina+1.3%

Personalis, Inc.-24.7%

By net margin

Illumina19.42%+41.7pp

NeoGenomics-13.3%-1.8pp

Natera, Inc.-14.61%-3.2pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Guardant Health-40.1%+13.7pp

Personalis, Inc.-148.11%-50.0pp

GRAIL, Inc.-253.22%+1,211pp

Profile

Guardant Health is a leading precision oncology company that develops advanced blood and tissue tests to provide critical insights across all stages of cancer care. The company leverages liquid biopsy technology, real-world data, and AI analytics to improve patient outcomes through early cancer screening, recurrence monitoring, and therapy selection for advanced-stage tumors.

Competitive position

A pioneer in liquid biopsy technology and the first to receive FDA approval for a comprehensive liquid biopsy companion diagnostic.

GeographiesUnited States, Global

Customer segmentsHealthcare Providers, Biopharmaceutical Companies, Patients, Medicare

Business modelDiagnostic Service Provider, B2B Data Licensing, Direct-to-Consumer

SuppliersNext-generation sequencing equipment manufacturers, Laboratory chemical and reagent suppliers, Cloud computing infrastructure providers

CustomersOncology clinics, Primary care networks, Pharmaceutical R&D departments, Health insurance companies

CountryUnited States of America

Listed2018

Employees1.8K

CEOHelmy Eltoukhy

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteguardanthealth.com

FilingsSEC EDGAR

Ask your AI about Guardant Health.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Guardant Health's market cap?: Guardant Health (GH) has a market capitalization of $20.7B and trades on NASDAQ.
What is Guardant Health's revenue and profitability?: Guardant Health generated $1.1B in trailing twelve-month revenue with a net loss of $433.2M, representing a net margin of -40.1%. Gross margin stands at 64.9%, with free cash flow of -$237.1M. These figures are based on the Q1 2026 filing.
Who are Guardant Health's competitors?: Guardant Health's key competitors include Grail, Natera, Illumina, and others. These companies compete in similar markets and product categories.
Where is Guardant Health headquartered?: Guardant Health is headquartered in United States of America and employs approximately 1,779 people. It has been publicly traded since 2018.